



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Volagidemab

| | |
|-----------|---|
| Cat. No.: | HY-P99383 |
| CAS No.: | 1233956-13-2 |
| Target: | GCGR |
| Pathway: | GPCR/G Protein |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

| | | | | | | | | | |
|--------------------|---|---------------|--|---------|---------|-----------------|-------------------------------|---------|---|
| Description | Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D) ^{[1][2]} . | | | | | | | | |
| In Vivo | <p>Volagidemab (5 mg/kg, s.c.) suppresses type 1 diabetes phenotype in Alloxan-induced diabetic mice^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table><tr><td>Animal Model:</td><td>Alloxan-induced diabetic mice^[2]</td></tr><tr><td>Dosage:</td><td>5 mg/kg</td></tr><tr><td>Administration:</td><td>Subcutaneous injection (s.c.)</td></tr><tr><td>Result:</td><td>Reduced phosphorylated CREB protein and PEPCK protein expression to nondiabetic levels.</td></tr></table> | Animal Model: | Alloxan-induced diabetic mice ^[2] | Dosage: | 5 mg/kg | Administration: | Subcutaneous injection (s.c.) | Result: | Reduced phosphorylated CREB protein and PEPCK protein expression to nondiabetic levels. |
| Animal Model: | Alloxan-induced diabetic mice ^[2] | | | | | | | | |
| Dosage: | 5 mg/kg | | | | | | | | |
| Administration: | Subcutaneous injection (s.c.) | | | | | | | | |
| Result: | Reduced phosphorylated CREB protein and PEPCK protein expression to nondiabetic levels. | | | | | | | | |

REFERENCES

[1]. Pettus J, et al. Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. *Nat Med.* 2022 Oct;28(10):2092-2099.

[2]. Wang MY, et al. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. *Proc Natl Acad Sci U S A.* 2015 Feb 24;112(8):2503-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA